<DOC>
	<DOCNO>NCT01747746</DOCNO>
	<brief_summary>The purpose study determine new drug call `` Rivaroxaban® '' effective preventing patient form clots heart rhythm reset cardiologist electrical device .</brief_summary>
	<brief_title>Anticoagulation With Rivaroxaban Cardioversion -The ARC Study</brief_title>
	<detailed_description>Patient electrically cardioverted require 1 month anticoagulation ( blood thinner ) . Rivaroxaban Xa-inhibitor show non-inferior Warfarin ( Vit K antagonist ) current standard care many treatment area . Rivaroxaban compare Warfarin historical control group study safety efficacy electrically cardioverted patient .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Patients nonvalvular atrial fibrillation require electrical cardioversion Atrial fibrillation unknown duration Patients require extend anticoagulation cardioversion due concomitant risk factor define CHADS2 score ≥ 1 Significant renal dysfunction ( CrCl &lt; 15mL/min ) Significant hepatic dysfunction ( ChildsPugh Class B C ) History coagulopathy Active bleeding Hypersensitivity Rivaroxaban Concomitant use anticoagulant Concomitant use potent CYP3A4/Pgp inhibitor inducer Interventions require interruption therapy Pregnancy Age &lt; 18 y/o History GI Bleed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Rivaroxaban</keyword>
	<keyword>Warfarin</keyword>
	<keyword>Anticoagulation</keyword>
	<keyword>Stroke</keyword>
	<keyword>Thrombo-embolism</keyword>
	<keyword>Bleeding</keyword>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>Cardioversion</keyword>
</DOC>